ImmunoForge Engages with Global Pharma at 2026 J.P. Morgan Healthcare Conference ImmunoForge will hold strategic meetings with pharmaceutical companies during the 2026 J.P. Morgan Healthcare Conference to advance its innovative treatments.

ImmunoForge Engages with Global Pharma at 2026 J.P. Morgan Healthcare Conference #South_Korea #Seoul #ImmunoForge #PF1801 #PF1804

ImmunoForge Receives FDA IND Approval for Phase 2 Clinical Trial of ‘Pemziviptadil’ for DMD Cardiomyopathy The U.S. Food and Drug Administration (FDA) has approved ImmunoForge's Phase 2 clinical trial IND for "Pemziviptadil (development code name PF1804)," a treatment for DMD (Duchenne Muscular Dystrophy) cardiomyopathy. A medication for DMD cardiomyopathy, pemziviptadil is used once a week and is based on ImmunForge’s ELP Platform (Elastin Like Polypeptide Platform), a long-acting pharmacological platform. In order to improve cardiac function, pemziviptadil, a vasoactive intestinal peptide (VIP), preferentially works on the vasoactive intestinal peptide receptor 2 (VPAC2) to promote heart contraction and relaxation.

ImmunoForge Receives FDA IND Approval for Phase 2 Clinical Trial of ‘Pemziviptadil’ for DMD Cardiomyopathy

👉 Read More: dmdwarrior.com

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #duchennesmusculardystrophy #musculardystrophy #gene #dna #ImmunoForge #Pemziviptadil #pf1804